Drugs / Polyethylene Glycol-treated Human Immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01596335 Comparator | May 2012 → Oct 2014 | Kawasaki disease | Tanabe Pharma Corporation | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyethylene Glycol-treated Human Immunoglobulin | “Polyethylene Glycol-treated Human Immunoglobulin (VGIH)” NCT01596335 ↗ |
| Known as | VGIH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01596335 ↗ |
| Modality | Protein / enzyme biologic | “Polyethylene Glycol-treated Human Immunoglobulin (VGIH)” NCT01596335 ↗ |
| Route | Intravenous | “administered by intravenous infusion slowly over at least 20 hours” NCT01596335 ↗ |